Incyte Appoints Bill Meury as CEO, Shares Rise 4.8% Pre-Market on M&A Hopes

Incyte Corporation has appointed Bill Meury as its new Chief Executive Officer following the retirement of longtime CEO Hervé Hoppenot. The leadership change has sparked investor optimism, with Incyte's shares rising 4.8% in pre-market trading. The transition is seen as a potential catalyst for increased mergers and acquisitions activity at the biopharmaceutical company. Separately, Roche announced upcoming executive committee changes as Hans Clevers and Barbara Schädler retire, with new leaders to be named soon. Oncolytics Biotech has appointed a former Ambrx executive as Chief Business Officer to lead its business development strategy. Applied DNA Sciences is focusing its operations on synthetic DNA manufacturing for biotherapeutics, consolidating activities under its LineaRx division. Additionally, Zynex has named Steven Dyson as its new CEO.